{"version":"1.0","type":"rich","provider_name":"Acast","provider_url":"https://acast.com","height":250,"width":700,"html":"<iframe src=\"https://embed.acast.com/$/67105af848726944170ab1fe/6a67a4ff4207b2a601cf89d6?\" frameBorder=\"0\" width=\"700\" height=\"250\"></iframe>","title":"Beaubrun and Acharya: No Antibiotic Without a Diagnostic","description":"<p>Antimicrobial resistance (AMR) isn't going to be solved by new antibiotics alone—it also requires identifying resistant infections quickly enough to guide treatment and prevent transmission. In this episode of <em>Behind the Breakthroughs</em>, Anne Beaubrun, PhD, of Cepheid and Amish Acharya, PhD, of the Fleming Initiative, discuss how rapid molecular diagnostics, including the TRACE-CPE study, could bring precision medicine to infectious disease by enabling earlier detection of carbapenemase-producing Enterobacterales (CPE)—dangerous, last-resort antibiotic-resistant bacteria that are spreading rapidly in hospitals. They also explore the scientific, clinical, and policy challenges of making rapid diagnostics a routine part of healthcare worldwide.</p><p><br></p><p>Produced and hosted by Jonathan D. Grinstein, PhD</p><p>Audio mixed and mastered by Erick Ziegler</p><p>Brought to you by Inside Precision Medicine (SAGE Publishing)</p>","author_name":"Inside Precision Medicine"}